Grandaxin (Tofisopam) is a benzodiazepine anxiolytic drug that is used in Russia and some European countries. Despite being a benzodiazepine derivative, pharmacological action of Grandaxin is differs from that of typical benzos because of the structural differences.
Grandaxin is a 2,3- benzodiazepine derivative and belongs to the novel class of drugs called homophthalazines. Tofisopam does not cause sedation or cognitive functions impairments; moreover, it may produce a moderate stimulative action, possibly by increasing the sensitivity of dopaminergic receptors.
The drug does not bind to benzodiazepine receptors, it is suggested that its anxiolytic effect is mediated through its effect on opioid signal transduction.
One of the most important advantages of Grandaxin over commonly used benzodiazepines is that Tofisopam does not form an addiction.
Indications for use are:
- Conditions followed by emotional tension, anxiety, apathy, and obsessive worrying
- Reactive depression
- Post-traumatic stress disorder
- Menopause (as a standalone therapy or as adjuvant therapy with hormonal preparations)
- Premenstrual syndrome
- Alcohol abstinence syndrome